adalimumab-adbm (Cyltezo) vs infliximab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Crohn's Disease

Shared mechanism: TNF-alpha · full Crohn's Disease pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Crohn's Diseasemonoclonal antibody
Reliable signal

NCT02871635 · Phase 3 · completed

This was a randomized, double-blind trial against the reference adalimumab product, with a validated Crohn's disease activity score as the primary endpoint. Clinical response at week 4 was similar in both groups (risk ratio 0.945, 90% CI 0.870 to 1.028), within the prespecified non-inferiority margin, and 147 people were randomized against a planned 130.

Hanauer et al. (Lancet Gastroenterol Hepatol, 2021; PMID 34388360) report different figures for this outcome, clinical response in 61 of 68 patients (90%) with BI 695501 and 68 of 72 (94%) with the reference product, because the registry figures are model-based least-squares means.

Reported efficacy

Percentage of Patients With a Clinical Response (CDAI Decrease of ≥70 Compared With Baseline) at Week 4: Clinical response (CDAI decrease of 70 points or more) at week 4, BI 695501 vs Humira (modified full analysis set): 61/68 (90%) vs 68/72 (94%); adjusted risk ratio 0.945 (90% CI 0.870 to 1.028), lower limit above the exploratory non-inferiority margin of 0.76 (Hanauer 2021, Lancet Gastroenterol Hepatol). (met)

Result source: NCT02871635

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Crohn's Diseasemonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00094458 · Phase 3 · completed

This meets the 'strong' test: randomized, triple-blinded (participant/investigator/outcomes assessor), active-comparator (not merely placebo) design, adequately powered (n=508), a primary endpoint that is a hard clinical measure (corticosteroid-free clinical remission via CDAI), and the primary comparisons reached statistical significance in the favorable direction for the key comparisons (combo vs AZA and IFX vs AZA).

Next expected readout: November 2026 · NCT05906576 (registry estimate)

Reported efficacy

Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Percentage of Participants With Corticosteriod-free Clinical Remission (Week 26): Azathioprine + Placebo 30.0% vs Infliximab + Placebo 44.4% vs Infliximab + Azathioprine 56.8%; p=<0.001 (Azathioprine + Placebo vs Infliximab + Azathioprine), p=0.006 (Azathioprine + Placebo vs Infliximab + Placebo), p=0.022 (Infliximab + Placebo vs Infliximab + Azathioprine) (met)

Result source: NCT00094458

Results for Crohn's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab
Clinical remission (induction)—Not reported47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (induction)—Not reported—Not posted · NCT00004941
Clinical remission (maintenance)68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT0287163566% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
Endoscopic response (maintenance)—Not reported—Not posted · NCT00004941

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
47.3% vs 34.1%vs Azathioprine + Placebowk 10 · n 169NCT00094458
5 other results
  • 59.8% vs 34.1% wk 10 · n 169 · Phase 3 · secondary NCT00094458
  • 49.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 52.1% vs 27.6% wk 6 · n 169 · Phase 3 · secondary NCT00094458
  • 32.5% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458
  • 36.7% vs 17.6% wk 2 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT00004941

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
68.6% vs 76.2%vs Humira EUwk 24 · n 68NCT02871635
infliximab
66% vs 54.7%vs Azathioprine + Placebowk 50 · n 97NCT00094458
7 other results
  • 74.1% vs 54.7% wk 50 · n 108 · Phase 3 · secondary NCT00094458
  • 72.2% vs 58.7% wk 42 · n 97 · Phase 3 · secondary NCT00094458
  • 73.1% vs 58.7% wk 42 · n 108 · Phase 3 · secondary NCT00094458
  • 66% vs 61.3% wk 34 · n 97 · Phase 3 · secondary NCT00094458
  • 69.4% vs 61.3% wk 34 · n 108 · Phase 3 · secondary NCT00094458
  • 47.9% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458
  • 60.4% vs 31.8% wk 26 · n 169 · Phase 3 · secondary NCT00094458

Endoscopic response (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT00004941
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 4 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricadalimumab-adbm (Cyltezo)infliximab
Dropout rate
25%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
28.4%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
34.3%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
0%
NCT01580670 · Phase 3 · monotherapy
13.3%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
5.6%BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
—BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
16.6%Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
11.8%Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
—W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
—
NCT01580670 · Phase 3 · monotherapy
2.2%
NCT00805766 · Phase 3 · monotherapy
18.2%
NCT00688636 · Phase 4 · registry result, not featured evidence
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
—BI 695501
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 2 more results
8.3%BI 695501 (Baseline - Week 24 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
2.8%BI 695501 (Week 24 - Week 46 + 10
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
—Infliximab + Azathioprinea
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 9 more results
—Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14%W30-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
16%W30-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
1.9%W50-Infliximab + Azathioprine
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.5%W50-Infliximab + Placebo
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
14.3%
NCT01580670 · Phase 3 · monotherapy
—
NCT00805766 · Phase 3 · monotherapy
9.1%
NCT00688636 · Phase 4 · registry result, not featured evidence
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
arthralgia 8.3%
respiratory tract infection 6.9%
crohn's disease 5.6%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
nasopharyngitis 6.9%
weight increased 4.2%
arthralgia 2.8%
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
a
nausea 21.8%
abdominal pain 13.4%
fatigue 13.4%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
show 6 more results
abdominal pain 20.9%
nausea 16.6%
arthralgia 14.1%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
abdominal pain 9.3%
nasopharyngitis 8.3%
crohn's disease 5.6%
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
abdominal pain 11.3%
nausea 11.3%
vomiting 11.3%
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
double stranded dna antibody positive 50%
gastroenteritis 21.4%
headache 21.4%
NCT01580670 · Phase 3 · monotherapy
infusion reaction 18.2% (placebo 7.7%)
abcess 9.1% (placebo 7.7%)
bronchitis 9.1% (placebo 0%)
NCT00688636 · Phase 4 · registry result, not featured evidence
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

adalimumab-adbm (Cyltezo)

CDAI ≥ 70 88% (n=68) vs 93.1% (n=72) Humira EU @ 4wk
responder rate · % of participants
NCT02871635 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
87.4% (n=68) vs 87.4% (n=72) Humira EU @ 24wk
NCT02871635 · Phase 3 · Crohn's Disease · phase 3

infliximab

Corticosteroid-free Clinical Remission 44.4% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 3 more results
56.8% (n=169) vs 30% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
60.8% (n=97) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
72.2% (n=108) vs 54.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Mucosal Healing 30.1% (n=93) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 1 more result
43.9% (n=107) vs 16.5% (n=109) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
CDAI 42.6% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
responder rate · % of participants
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 15 more results
47.3% (n=169) vs 22.4% (n=170) Azathioprine + Placebo @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
63.3% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55.6% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
69.2% (n=169) vs 39.4% (n=170) Azathioprine + Placebo @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
55% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.7% (n=169) vs 38.8% (n=170) Azathioprine + Placebo @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
54.4% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
62.1% (n=169) vs 37.6% (n=170) Azathioprine + Placebo @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
76.3% (n=97) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
76.9% (n=108) vs 66.7% (n=75) Azathioprine + Placebo @ 34wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
74.2% (n=97) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
77.8% (n=108) vs 65.3% (n=75) Azathioprine + Placebo @ 42wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
72.2% (n=97) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
78.7% (n=108) vs 62.7% (n=75) Azathioprine + Placebo @ 50wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
IBDQ Total 27.7 vs 20.1 Azathioprine + Placebo score @ 2wk
absolute change · score
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
31.4 vs 20.1 Azathioprine + Placebo score @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
34.8 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
39.9 vs 28.3 Azathioprine + Placebo score @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
37.8 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
42.4 vs 31 Azathioprine + Placebo score @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
43.7 vs 30.3 Azathioprine + Placebo score @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
39.9 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
45.2 vs 31.4 Azathioprine + Placebo score @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
Average Corticosteroid Use mg Per 21.2 vs 22.92 Azathioprine + Placebo per day @ 2wk
absolute value · per day
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
show 9 more results
22.75 vs 22.92 Azathioprine + Placebo per day @ 2wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
17.68 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
18.26 vs 18.56 Azathioprine + Placebo per day @ 6wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
15.68 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
15.01 vs 16.19 Azathioprine + Placebo per day @ 10wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
13.23 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
11.64 vs 13.49 Azathioprine + Placebo per day @ 18wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
10.96 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · Crohn's Disease · phase 3
9.35 vs 11.57 Azathioprine + Placebo per day @ 26wk
NCT00094458 · Phase 3 · combination · Crohn's Disease · phase 3
PCDAI 78.6% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
100% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
92.9% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
100% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI 85.7% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI -20.71 score @ 2wk
absolute change · score
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
-27.68 score @ 6wk
NCT01580670 · Phase 3 · monotherapy
-30 score @ 10wk
NCT01580670 · Phase 3 · monotherapy
-28.57 score @ 14wk
NCT01580670 · Phase 3 · monotherapy
-31.07 score @ 18wk
NCT01580670 · Phase 3 · monotherapy
-27.32 score @ 22wk
NCT01580670 · Phase 3 · monotherapy
-30.18 score @ 26wk
NCT01580670 · Phase 3 · monotherapy
-26.07 score @ 30wk
NCT01580670 · Phase 3 · monotherapy
-30.21 score @ 34wk
NCT01580670 · Phase 3 · monotherapy
-26.25 score @ 38wk
NCT01580670 · Phase 3 · monotherapy
-30.42 score @ 42wk
NCT01580670 · Phase 3 · monotherapy
-27.08 score @ 46wk
NCT01580670 · Phase 3 · monotherapy
-32.5 score @ 50wk
NCT01580670 · Phase 3 · monotherapy
-28.33 score @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI -26.25 score @ 54wk
absolute change · score
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 42.9% (n=14) @ 2wk
responder rate · % of participants
No placebo or comparator arm
NCT01580670 · Phase 3 · monotherapy
show 13 more results
78.6% (n=14) @ 6wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 10wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 14wk
NCT01580670 · Phase 3 · monotherapy
85.7% (n=14) @ 18wk
NCT01580670 · Phase 3 · monotherapy
71.4% (n=14) @ 22wk
NCT01580670 · Phase 3 · monotherapy
78.6% (n=14) @ 26wk
NCT01580670 · Phase 3 · monotherapy
64.3% (n=14) @ 30wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 34wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 38wk
NCT01580670 · Phase 3 · monotherapy
83.3% (n=14) @ 42wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 46wk
NCT01580670 · Phase 3 · monotherapy
91.7% (n=14) @ 50wk
NCT01580670 · Phase 3 · monotherapy
75% (n=14) @ 54wk
NCT01580670 · Phase 3 · monotherapy
PCDAI Remission 64.3% (n=14) @ 54wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01580670 · Phase 3 · monotherapy
CDAI 95 score @ 8wk
absolute change · score
No placebo or comparator arm
NCT00805766 · Phase 3 · monotherapy
show 10 more results
163 score @ 4wk
NCT00805766 · Phase 3 · monotherapy
95 score @ 8wk
NCT00805766 · Phase 3 · monotherapy
161 score @ 12wk
NCT00805766 · Phase 3 · monotherapy
95 score @ 16wk
NCT00805766 · Phase 3 · monotherapy
164 score @ 20wk
NCT00805766 · Phase 3 · monotherapy
100 score @ 24wk
NCT00805766 · Phase 3 · monotherapy
156.5 score @ 28wk
NCT00805766 · Phase 3 · monotherapy
110 score @ 32wk
NCT00805766 · Phase 3 · monotherapy
139 score @ 36wk
NCT00805766 · Phase 3 · monotherapy
95 score @ 40wk
NCT00805766 · Phase 3 · monotherapy

+ 5 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: TNF-alpha · full Ulcerative Colitis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Ulcerative Colitismonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Ulcerative Colitismonoclonal antibody (chimeric IgG1)
Weak signal

NCT01585155 · Phase 3 · completed

No randomization, no blinding (masking: NONE), no control arm, single-group design with only 21 patients — this defaults to 'weak' per the design rules regardless of the favorable-looking remission percentages.

Next expected readout: December 2026 · NCT06839820 (registry estimate)

Reported efficacy

Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): Percent of Patients Who Achieved CAI Remission (Weeks 2, 6, 8, 10, 14, 18, 22, 26, 30, and the last time point during the period from administration of the study drug to Week 30): TA-650 — Weeks 2: 60%; Weeks 6: 80%; Weeks 8: 80%; Weeks 10: 77.8%; Weeks 14: 87.5%; Weeks 18: 87.5%; Weeks 22: 64.3%; Weeks 26: 85.7%; Weeks 30: 64.3%; The last time point: 42.9%

Result source: NCT01585155

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab
Clinical remission (induction)—Not reported—Trial running · NCT06614387
Clinical remission (maintenance)—Not reported—Trial running · NCT06614387
Clinical response (induction)—Not reported—Trial running · NCT06614387
Endoscopic improvement (induction)—Not reported—Trial running · NCT06614387
Corticosteroid-free remission (maintenance)—Not reported—Trial running · NCT06614387

Clinical remission (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Trial running · NCT06614387

Clinical remission (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Trial running · NCT06614387

Clinical response (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Trial running · NCT06614387

Endoscopic improvement (induction)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Trial running · NCT06614387

Corticosteroid-free remission (maintenance)

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Trial running · NCT06614387
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
23.8%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
47.8%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Discontinued due to AEs
4.8%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
26.1%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
13.6%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
50%
NCT00791557 · Phase na · registry result, not featured evidence
Serious AEs
14.3%a
NCT01585155 · Phase 3 · monotherapy
show 3 more results
21.7%5 mg/kg every 12 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
18.2%5 mg/kg every 8 weeks
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%
NCT00791557 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
double stranded dna antibody positive 57.1%
nasopharyngitis 33.3%
acne 9.5%
NCT01585155 · Phase 3 · monotherapy
show 3 more results
5 mg/kg every 12 weeks
colitis ulcerative 65.2%
upper respiratory tract infection 26.1%
pain 17.4%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5 mg/kg every 8 weeks
colitis ulcerative 31.8%
upper respiratory tract infection 31.8%
fever 27.3%
NCT00336492 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
bone marrow suppression 50%
infection 50%
infusion reaction 50%
NCT00791557 · Phase na · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 2 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

Clinical Remission 60% (n=21) @ 2wk
responder rate · % of participants
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 6wk
responder rate · % of participants
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 80% (n=21) @ 8wk
responder rate · % of participants
No placebo or comparator arm
Weeks 8
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 77.8% (n=21) @ 10wk
responder rate · % of participants
No placebo or comparator arm
Weeks 10
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 14wk
responder rate · % of participants
No placebo or comparator arm
Weeks 14
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 87.5% (n=21) @ 18wk
responder rate · % of participants
No placebo or comparator arm
Weeks 18
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 22wk
responder rate · % of participants
No placebo or comparator arm
Weeks 22
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 85.7% (n=21) @ 26wk
responder rate · % of participants
No placebo or comparator arm
Weeks 26
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 64.3% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
Weeks 30
NCT01585155 · Phase 3 · monotherapy
Clinical Remission 42.9% (n=21) @ 30wk
responder rate · % of participants
No placebo or comparator arm
The last time point
NCT01585155 · Phase 3 · monotherapy
CAI 4 score @ 2wk
absolute change · score
No placebo or comparator arm
Weeks 2
NCT01585155 · Phase 3 · monotherapy
CAI 3.5 score @ 6wk
absolute change · score
No placebo or comparator arm
Weeks 6
NCT01585155 · Phase 3 · monotherapy

+ 31 further endpoints in the CSV export.

Psoriasis

Shared mechanism: TNF-alpha · full Psoriasis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Psoriasismonoclonal antibody
Weak signal

NCT03210259 · Phase 3 · completed

After a 14-week Humira run-in, 238 patients were randomized to switch between Cyltezo and Humira or continue Humira in a double-blind active-controlled period. Both primary pharmacokinetic comparisons met the prespecified equivalence range, but these were drug-level measures rather than direct clinical psoriasis outcomes, so the evidence is moderate. Its registered primary outcomes are pharmacokinetic measures with no comparison, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Psoriasismonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00106847 · Phase 3 · completed

This randomized, double-blind trial enrolled 683 patients and measured the proportion achieving at least 75% skin clearance (PASI 75), a standard psoriasis efficacy measure, at week 10. Infliximab produced clearance rates of 70-75% depending on dose, compared with 2% on placebo, a highly statistically significant difference.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2030 · NCT07352566 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved a Greater Than Equal to 75 Percent Response in Psoriasis Area and Severity Index (PASI) (Week 10): PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001) (met)

Result source: NCT01177800

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab
PASI 75—Not reported81% vs 2.2%+78.8 vs placebowk 10 · n 84NCT01177800
PASI 90—Not reported—Not posted · NCT00106847
PASI 100—Not reported—Not posted · NCT00106847
sPGA 0/1—Not reported88.1% vs 6.7%+81.4 vs placebowk 10 · n 84NCT01177800
1 other result
  • 0.8% vs 0.4% wk 16 · n 653 · Phase 3 · secondary NCT00251641
DLQI, change—Not reported-8 vs -1.5−6.5 vs placebowk 10 · n 84NCT01177800

PASI 75

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
81% vs 2.2%+78.8 vs placebowk 10 · n 84NCT01177800

PASI 90

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT00106847

PASI 100

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT00106847

sPGA 0/1

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
88.1% vs 6.7%+81.4 vs placebowk 10 · n 84NCT01177800
1 other result
  • 0.8% vs 0.4% wk 16 · n 653 · Phase 3 · secondary NCT00251641

DLQI, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
-8 vs -1.5−6.5 vs placebowk 10 · n 84NCT01177800
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Psoriasis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
11.9%a
NCT01177800 · Phase 3
show 17 more results
18.4%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
16.7%
NCT00527072 · Phase 3 · registry result, not featured evidence
0%
NCT00629772 · Phase 3 · registry result, not featured evidence
18.9%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
26.1%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
17.2%
NCT00251641 · Phase 3 · registry result, not featured evidence
13.6%5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
10.7%a
NCT01177800 · Phase 3
show 17 more results
7.9%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
—TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
6%
NCT00527072 · Phase 3 · registry result, not featured evidence
—
NCT00629772 · Phase 3 · registry result, not featured evidence
3.8%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
8.7%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
12.3%
NCT00251641 · Phase 3 · registry result, not featured evidence
—5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Serious AEs
4.8%a
NCT01177800 · Phase 3
show 17 more results
18.4%5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
9.8%TA-650(Dose Escalation Period)Over
NCT01680159 · Phase 3 · registry result, not featured evidence
12.9%TA-650(Dose Escalation Period)Plaq
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Dose Escalation Period)Psor
NCT01680159 · Phase 3 · registry result, not featured evidence
14.3%TA-650(Dose Escalation Period)Pust
NCT01680159 · Phase 3 · registry result, not featured evidence
11.1%TA-650(Entire Evaluation Period)Pl
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Entire Evaluation Period)Ps
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Overall
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Plaque P
NCT01680159 · Phase 3 · registry result, not featured evidence
0%TA-650(Normal Dose Period)Psoriati
NCT01680159 · Phase 3 · registry result, not featured evidence
3.7%
NCT00527072 · Phase 3 · registry result, not featured evidence
16.7%
NCT00629772 · Phase 3 · registry result, not featured evidence
1.3%5 mg/kg
NCT00687401 · Phase 3 · registry result, not featured evidence
17.4%5 mg/kg
NCT00686686 · Phase 3 · registry result, not featured evidence
6.8%
NCT00251641 · Phase 3 · registry result, not featured evidence
0%5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
upper respiratory tract infection 14.3% (placebo 11.1%)
antinuclear antibody positive 11.9% (placebo 6.7%)
asthenia 11.9% (placebo 11.1%)
NCT01177800 · Phase 3
show 17 more results
5 mg/kg
pruritus 10.5%
rhinitis 7.9%
blood triglycerides increased 5.3%
NCT00686595 · Phase 4 · registry result, not featured evidence
double stranded dna antibody positive 49%
nasopharyngitis 27.5%
headache 7.8%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 58.1%
nasopharyngitis 22.6%
dyspnoea 9.7%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 25%
alanine aminotransferase increased 12.5%
arthralgia 12.5%
NCT01680159 · Phase 3 · registry result, not featured evidence
nasopharyngitis 60%
double stranded dna antibody positive 40%
alanine aminotransferase increased 20%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 42.9%
nasopharyngitis 42.9%
chapped lips 14.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 69.4%
nasopharyngitis 22.2%
dyspnoea 8.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 60%
alanine aminotransferase increased 10%
arthralgia 10%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 34.8%
nasopharyngitis 8.7%
psoriasis 4.3%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 33.3%
nasopharyngitis 11.1%
aspartate aminotransferase increased 2.8%
NCT01680159 · Phase 3 · registry result, not featured evidence
double stranded dna antibody positive 40%
erythema 10%
feeling hot 10%
NCT01680159 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 9.8%
arthralgia 8.8%
headache 6.5%
NCT00527072 · Phase 3 · registry result, not featured evidence
common cold 25% (placebo 25%)
fatigue 16.7% (placebo 8.3%)
joint pain in hand 16.7% (placebo 0%)
NCT00629772 · Phase 3 · registry result, not featured evidence
5 mg/kg
pyrexia 5.7%
arthralgia 5%
NCT00687401 · Phase 3 · registry result, not featured evidence
5 mg/kg
hepatic enzyme increased 13%
asthenia 8.7%
folliculitis 8.7%
NCT00686686 · Phase 3 · registry result, not featured evidence
nasopharyngitis 18.3%
infusion related reaction 10.8%
headache 10.2%
NCT00251641 · Phase 3 · registry result, not featured evidence
5 mg/kg
pyrexia 18.2%
cough 13.6%
oropharyngeal pain 13.6%
NCT00687362 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

PASI 75 81% (n=84) vs 2.2% (n=45) placebo @ 10wk
responder rate · % of participants
NCT01177800 · Phase 3
DLQI -8 vs -1.5 placebo score @ 10wk
absolute change · score
NCT01177800 · Phase 3
show 1 more result
-10.3 vs -9.2 placebo score @ 26wk
NCT01177800 · Phase 3
sPGA 0/1 88.1% (n=84) vs 6.7% (n=45) placebo @ 10wk
responder rate · % of participants
NCT01177800 · Phase 3
show 2 more results
0.76% (n=653) vs 0.38% (n=215) Methotrexate @ 16wk
NCT00251641 · Phase 3 · registry result, not featured evidence
0.73% (n=653) vs 0.28% (n=215) Methotrexate @ 26wk
NCT00251641 · Phase 3 · registry result, not featured evidence
PASI 75 71% (n=35) @ 10wk5 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence
show 3 more results
94% (n=32) @ 18wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
74% (n=35) @ 24wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
72.7% (n=22) @ 10wk*5 mg/kg
NCT00687362 · Phase 2 · registry result, not featured evidence · converted to % from 16 participants as posted
PASI 50 91% (n=35) @ 10wk5 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence
show 4 more results
97% (n=32) @ 18wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
89% (n=35) @ 24wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
79.1% (n=211) @ 10wk*
NCT00527072 · Phase 3 · registry result, not featured evidence · converted to % from 167 participants as posted
64.6% (n=209) @ 26wk*
NCT00527072 · Phase 3 · registry result, not featured evidence · converted to % from 135 participants as posted
PASI 90 37% (n=35) @ 10wk5 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence
show 2 more results
56% (n=32) @ 18wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
54% (n=35) @ 24wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
PASI 100 17% (n=35) @ 10wk5 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence
show 2 more results
31% (n=32) @ 18wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
40% (n=35) @ 24wk5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence
SAPASI -89% (n=31) @ 18wk5 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 89 Percent reduction as posted
show 1 more result
-82% (n=33) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 82 Percent reduction as posted
BSA -82% (n=32) @ 18wk5 mg/kg
absolute change · percentage points
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 82 Percent reduction as posted
show 1 more result
-72% (n=35) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 72 Percent reduction as posted
Pruritus VAS -81% (n=30) @ 18wk5 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 81 Percent reduction as posted
show 1 more result
-72% (n=33) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 72 Percent reduction as posted
DLQI -77% (n=30) @ 18wk5 mg/kg
percent change · % of baseline
No placebo or comparator arm
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 77 Percent reduction as posted
show 2 more results
-68% (n=31) @ 24wk*5 mg/kg
NCT00686595 · Phase 4 · registry result, not featured evidence · converted to % from 68 Percent reduction as posted
63.45% (n=12) @ 26wk
NCT00629772 · Phase 3 · registry result, not featured evidence
sPGA 0/1 65.4% (n=211) @ 10wk
responder rate · % of participants
No placebo or comparator arm
NCT00527072 · Phase 3 · registry result, not featured evidence · converted to % from 138 participants as posted

+ 8 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline

adalimumab-adbm (Cyltezo)

Marketed by Boehringer Ingelheim

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02137226 · Phase 3 · completed

The 645-participant study was randomized, double-blind, and active-controlled against US-licensed Humira, with ACR20 response as the primary clinical endpoint. The prespecified equivalence margins were met at both Week 12 and Week 24, so the comparison supports equivalent clinical response between BI 695501 and Humira.

No aligned efficacy figure on record for this race.

infliximab · Remicade

Marketed by Johnson & Johnson

Approved in Rheumatoid Arthritismonoclonal antibody (chimeric IgG1)
Reliable signal

NCT00269867 · Phase 3 · completed

This randomised, double-blind, placebo-controlled trial in 428 patients with rheumatoid arthritis (ATTRACT) reported ACR20 responses of 50-58% across the infliximab plus methotrexate regimens against 20% on placebo plus methotrexate at week 30 (P<0.001 for each regimen), on a validated measure of disease activity.

Next expected readout: March 2028 · NCT03414502 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointadalimumab-adbm (Cyltezo)infliximab
ACR20—Not reported56.6% vs 53%vs Remicade-USwk 22 · n 228NCT02990806
51 other results
  • 52% vs 46.4% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 55.3% vs 46.4% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 47.2% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 46.4% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 56.9% vs 46.4% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 48.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 55.8% vs 48.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 49.2% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 50.8% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 50% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.9% vs 50% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 50.8% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 50.8% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 51.1% vs 48% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 51.3% vs 48% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 53.7% vs 50% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 50% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 53.6% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 53.6% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 57.3% vs 54.4% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 60.9% vs 54.4% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 52% vs 47.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 47.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 48.8% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 48.8% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 61.7% vs 55.6% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 55.6% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 62.1% vs 56.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 56.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 55.5% vs 48.8% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 48.8% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 58.1% vs 50% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.4% vs 50% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 56.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 61.9% vs 56.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 60.8% vs 55.6% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 62.4% vs 55.6% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 54.5% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 55.9% vs 56.3% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 62.6% vs 61.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 62.6% vs 62.3% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 51.1% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 56.8% vs 52.2% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 47.1% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 46.7% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 31.3% vs 32.5% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 29.1% vs 31.8% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 56.7% vs 32.3% wk 14 · n 30 · Phase 2 · secondary NCT01313520
ACR50—Not reported30.8% vs 32.7%vs Remicade USwk 62 · n 227NCT02990806
50 other results
  • 28.4% vs 32.7% wk 62 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 27.9% vs 32.7% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.7% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 32.7% wk 58 · n 446 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.3% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 33.5% vs 32.3% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 36.6% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 28.6% wk 54 · n 446 · Phase 3 · secondary NCT02990806
  • 36.1% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 37% vs 34.7% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 35.5% vs 34.7% wk 50 · n 446 · Phase 3 · secondary NCT02990806
  • 34.8% vs 34.3% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 34.5% vs 34.3% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 30.8% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.5% wk 46 · n 446 · Phase 3 · secondary NCT02990806
  • 29.5% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 31.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 40.6% vs 36.7% wk 42 · n 446 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 37.1% vs 36.7% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 31.3% vs 30.2% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 30.2% wk 38 · n 446 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 30.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.3% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.3% wk 34 · n 446 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.7% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.7% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 30% vs 28.6% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 30 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 28.2% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 28.2% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 34.4% vs 32.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 31% vs 32.3% wk 26 · n 446 · Phase 3 · secondary NCT02990806
  • 33% vs 31.9% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.9% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 27.8% vs 25.6% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 27.8% vs 26.7% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.9% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 31.7% vs 29.6% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 24.7% vs 21.3% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 23.3% vs 21.7% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 19.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.9% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 8.4% vs 8.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 6.6% vs 6.7% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 20% vs 0% wk 14 · n 30 · Phase 2 · secondary NCT01313520
ACR70—Not reported17.2% vs 18.5%vs Remicade USwk 62 · n 227NCT02990806
49 other results
  • 13.2% vs 18.5% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 18.1% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 15.2% vs 18.1% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 18.9% vs 19.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 16.2% vs 19.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.1% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.1% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 14.9% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 14.9% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 13.3% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 13.7% vs 13.3% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 22% vs 23% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 23% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 20.7% vs 22.6% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 22.6% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 15% vs 18.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 16.9% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 16.9% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 18.5% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.3% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 17.3% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 17.6% vs 15.7% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 15.7% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 16.1% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.2% vs 16.1% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 18.1% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 20.8% vs 18.1% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 16.7% vs 16.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 19.3% vs 16.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 15.3% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 15.3% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 14.1% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 11.7% vs 14.1% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 14.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 14.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 15.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 12.7% vs 15.3% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 10.6% vs 12.1% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 11% vs 11.2% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 15% vs 11.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 14.5% vs 11% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 11% vs 7.8% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 9.7% vs 7.4% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 6.6% vs 7.2% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 5.7% vs 6.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.1% wk 2 · n 227 · Phase 3 · secondary NCT02990806
DAS28-CRP remission—Not reported—Not posted · NCT01217086
HAQ-DI, change—Not reported-0.5 vs -0.5vs Remicade USwk 62 · n 227NCT02990806
24 other results
  • -0.4 vs -0.5 wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.3 wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • -0.2 vs -0.3 wk 2 · n 227 · Phase 3 · secondary NCT02990806
Modified Sharp score, change—Not reported—Not posted · NCT01217086

ACR20

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
56.6% vs 53%vs Remicade-USwk 22 · n 228NCT02990806
51 other results
  • 52% vs 46.4% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 55.3% vs 46.4% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 47.2% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 46.4% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 56.9% vs 46.4% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 48.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 55.8% vs 48.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 52.4% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 49.2% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 47.2% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 50.8% vs 47.2% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 54.2% vs 50% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.9% vs 50% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 50.8% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 50.8% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 51.1% vs 48% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 51.3% vs 48% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 53.7% vs 50% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 54.3% vs 50% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 54.6% vs 53.6% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 53.6% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 57.3% vs 54.4% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 60.9% vs 54.4% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 52% vs 47.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 47.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 56.4% vs 48.8% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 59.4% vs 48.8% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 61.7% vs 55.6% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 55.6% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 62.1% vs 56.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 61.4% vs 56.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 55.5% vs 48.8% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.9% vs 48.8% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 58.1% vs 50% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 57.4% vs 50% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 62.6% vs 56.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 61.9% vs 56.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 60.8% vs 55.6% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 62.4% vs 55.6% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 56.8% vs 54.5% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 55.9% vs 56.3% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 62.6% vs 61.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 62.6% vs 62.3% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 56.4% vs 51.1% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 56.8% vs 52.2% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 47.1% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 46.7% vs 54.3% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 31.3% vs 32.5% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 29.1% vs 31.8% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 56.7% vs 32.3% wk 14 · n 30 · Phase 2 · secondary NCT01313520

ACR50

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
30.8% vs 32.7%vs Remicade USwk 62 · n 227NCT02990806
50 other results
  • 28.4% vs 32.7% wk 62 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 32.7% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 27.9% vs 32.7% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.7% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 32.7% wk 58 · n 446 · Phase 3 · secondary NCT02990806
  • 32.6% vs 32.3% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 33.5% vs 32.3% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 36.6% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 28.6% wk 54 · n 446 · Phase 3 · secondary NCT02990806
  • 36.1% vs 28.6% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 37% vs 34.7% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 35.5% vs 34.7% wk 50 · n 446 · Phase 3 · secondary NCT02990806
  • 34.8% vs 34.3% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 34.5% vs 34.3% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 30.8% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.5% wk 46 · n 446 · Phase 3 · secondary NCT02990806
  • 29.5% vs 31.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 31.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 40.6% vs 36.7% wk 42 · n 446 · Phase 3 · secondary NCT02990806
  • 33.5% vs 36.7% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 37.1% vs 36.7% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 31.3% vs 30.2% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 34% vs 30.2% wk 38 · n 446 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.6% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 32.5% vs 30.6% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.3% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.3% wk 34 · n 446 · Phase 3 · secondary NCT02990806
  • 35.2% vs 34.7% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 39.1% vs 34.7% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 30% vs 28.6% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 29.4% vs 28.6% wk 30 · n 446 · Phase 3 · secondary NCT02990806
  • 29.1% vs 28.2% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 28.4% vs 28.2% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 34.4% vs 32.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 31% vs 32.3% wk 26 · n 446 · Phase 3 · secondary NCT02990806
  • 33% vs 31.9% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 30.5% vs 31.9% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 27.8% vs 25.6% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 27.8% vs 26.7% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 32.2% vs 30.9% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 31.7% vs 29.6% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 24.7% vs 21.3% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 23.3% vs 21.7% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 16.3% vs 19.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.9% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 8.4% vs 8.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 6.6% vs 6.7% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 20% vs 0% wk 14 · n 30 · Phase 2 · secondary NCT01313520

ACR70

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
17.2% vs 18.5%vs Remicade USwk 62 · n 227NCT02990806
49 other results
  • 13.2% vs 18.5% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 18.1% wk 62 · n 227 · Phase 3 · secondary NCT02990806
  • 15.2% vs 18.1% wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • 18.9% vs 19.8% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 16.2% vs 19.8% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.1% wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.1% wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 14.9% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 14.9% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 13.3% wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • 13.7% vs 13.3% wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • 22% vs 23% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 23% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 20.7% vs 22.6% wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 22.6% wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • 15% vs 18.5% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 18.5% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 16.9% wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 16.9% wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • 17.2% vs 18.5% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 18.3% vs 18.5% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 14.5% vs 17.3% wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • 15.7% vs 17.3% wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • 17.6% vs 15.7% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.7% vs 15.7% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 16.1% wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • 14.2% vs 16.1% wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • 18.1% vs 18.1% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 20.8% vs 18.1% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 16.7% vs 16.9% wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • 19.3% vs 16.9% wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 15.3% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 15.3% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 14.1% wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • 11.7% vs 14.1% wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • 16.3% vs 14.5% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 13.2% vs 14.5% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 15.4% vs 15.3% wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • 12.7% vs 15.3% wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • 10.6% vs 12.1% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 11% vs 11.2% wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • 15% vs 11.7% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 14.5% vs 11% wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • 11% vs 7.8% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 9.7% vs 7.4% wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • 6.6% vs 7.2% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 5.7% vs 6.1% wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.3% wk 2 · n 227 · Phase 3 · secondary NCT02990806
  • 0.9% vs 1.1% wk 2 · n 227 · Phase 3 · secondary NCT02990806

DAS28-CRP remission

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT01217086

HAQ-DI, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
-0.5 vs -0.5vs Remicade USwk 62 · n 227NCT02990806
24 other results
  • -0.4 vs -0.5 wk 62 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 58 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 58 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 54 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 54 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.6 wk 50 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 46 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 46 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 227 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 42 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 38 · n 197 · Phase 3 · secondary NCT02990806
  • -0.5 vs -0.5 wk 34 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 34 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.5 wk 30 · n 197 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 26 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 26 · n 197 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 22 · n 227 · Phase 3 · secondary NCT02990806
  • -0.4 vs -0.4 wk 18 · n 227 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.3 wk 14 · n 227 · Phase 3 · secondary NCT02990806
  • -0.3 vs -0.4 wk 6 · n 227 · Phase 3 · secondary NCT02990806
  • -0.2 vs -0.3 wk 2 · n 227 · Phase 3 · secondary NCT02990806

Modified Sharp score, change

adalimumab-adbm (Cyltezo)
—Not reported
infliximab
—Not posted · NCT01217086
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

adalimumab-adbm (Cyltezo): registry results are on file for Rheumatoid Arthritis, but their comparison mappings are not yet available.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. adalimumab-adbm (Cyltezo): 0 of 4 rows · infliximab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricinfliximab
Dropout rate
—Infliximab + Methotrexate (Moderata
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
14.6%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
—Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
—Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
38%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
6.1%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
0%
NCT01313520 · Phase 2 · registry result, not featured evidence
10%
NCT00948610 · Phase na · registry result, not featured evidence
Discontinued due to AEs
—Infliximab + Methotrexate (Moderata
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
5.4%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
—Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
—Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
17.4%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
4.9%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
—
NCT01313520 · Phase 2 · registry result, not featured evidence
—
NCT00948610 · Phase na · registry result, not featured evidence
Serious AEs
1.9%Infliximab + Methotrexate (Moderata
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 13 more results
1.5%Infliximab + Methotrexate (Severe
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
8.4%Stage 1, 2 and 3: NI-071 Group
NCT02990806 · Phase 3 · registry result, not featured evidence
6.6%Stage 2 and Stage 3: Remicade US t
NCT02990806 · Phase 3 · registry result, not featured evidence
13%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
—10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
8.7%10 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
4.8%6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
7.1%3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
5.2%Open-label
NCT00691028 · Phase 3 · registry result, not featured evidence
0%
NCT01313520 · Phase 2 · registry result, not featured evidence
0%
NCT00948610 · Phase na · registry result, not featured evidence
Most frequent reported AEs
a
hepatic function disnormal 50%
upper respiratory infection 27.9%
fever 3.8%
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 9 more results
hepatic function disnormal 37.7%
upper respiratory infection 30%
hypolekocytosis 10.8%
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
nasopharyngitis 12.3%
upper respiratory tract infection 10.6%
headache 7%
NCT02990806 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.7%
upper respiratory tract infection 10.2%
alanine aminotransferase increased 6.6%
NCT02990806 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 20.7%
pruritus 12%
urticaria 9.8%
NCT00732875 · Phase 3 · registry result, not featured evidence · combination
10 mg/kg
dna antibody positive 51.9%
nasopharyngitis 28.8%
antinuclear antibody positive 16.3%
NCT00691028 · Phase 3 · registry result, not featured evidence
6 mg/kg
dna antibody positive 55.8%
nasopharyngitis 27.9%
antinuclear antibody positive 14.4%
NCT00691028 · Phase 3 · registry result, not featured evidence
3 mg/kg
dna antibody positive 65.7%
nasopharyngitis 29.3%
antinuclear antibody positive 25.3%
NCT00691028 · Phase 3 · registry result, not featured evidence
nasopharyngitis 17.1%
alanine aminotransferase increased 10.1%
aspartate aminotransferase increased 6.1%
NCT00691028 · Phase 3 · registry result, not featured evidence
joint swelling 13.3% (placebo 19.4%)
headache 6.7% (placebo 0%)
palpitations 6.7% (placebo 0%)
NCT01313520 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

infliximab

EULAR Good, Moderate 49.7% (n=197) @ 10wk3 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00714493 · Phase 4 · registry result, not featured evidence
show 1 more result
51.8% (n=197) @ 26wk3 mg/kg
NCT00714493 · Phase 4 · registry result, not featured evidence
HAQ-DI -0.59 score @ 54wk10 mg/kg
absolute change · score
No placebo or comparator arm
NCT00691028 · Phase 3 · registry result, not featured evidence
show 6 more results
-0.56 score @ 54wk6 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
-0.173 score @ 10wk3 mg/kg
NCT00714493 · Phase 4 · registry result, not featured evidence
-0.223 score @ 26wk3 mg/kg
NCT00714493 · Phase 4 · registry result, not featured evidence
-0.48 score @ 54wk3 mg/kg
NCT00691028 · Phase 3 · registry result, not featured evidence
-0.59 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
-0.83 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ACR20 28.4% (n=197) @ 10wk3 mg/kg
responder rate · % of participants
No placebo or comparator arm
NCT00714493 · Phase 4 · registry result, not featured evidence
show 3 more results
35.5% (n=197) @ 26wk3 mg/kg
NCT00714493 · Phase 4 · registry result, not featured evidence
63.46% (n=104) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
76.15% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ACR50 47.12% (n=104) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
57.69% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
ACR70 29.81% (n=104) @ 26wk
responder rate · % of participants
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
29.23% (n=130) @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Swollen Joint Count -2.6 Swollen joints @ 26wk
absolute change · Swollen joints
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-7.7 Swollen joints @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
TJC -4 Tender joints @ 26wk
absolute change · Tender joints
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-10.6 Tender joints @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Pain VAS -26.8 score @ 26wk
absolute change · score
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-37.3 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Patient Global Assessment -28.3 score @ 26wk
absolute change · score
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-39.3 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Physician Global Assessment -25.3 score @ 26wk
absolute change · score
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-36.4 score @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
Morning Stiffness Duration -36.63 minutes @ 26wk
absolute change · minutes
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-77.12 minutes @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
CRP Change -0.54 mg @ 26wk
absolute change · mg
No placebo or comparator arm
NCT00896168 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
-1.22 mg @ 26wk
NCT00896168 · Phase 4 · registry result, not featured evidence · combination

+ 16 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab-adbm (Cyltezo)'s landscape · infliximab's landscape